Researchers in two countries say they have found that the class of drugs that includes Avandia and Actos doubles the risk of heart failure in diabetes patients. The study by U.S. and U.K. researchers, who analyzed previous studies and case reports to reach their determination, tends to confirm a May study that raised U.S. concerns with GlaxoSmithKline's Avandia.

Related Summaries